Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1 - Gastrointestinal tumours, upper digestive 

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial

Date

20 Oct 2023

Session

Proffered Paper session 1 - Gastrointestinal tumours, upper digestive 

Topics

Tumour Site

Gastro-Oesophageal Junction Cancer

Presenters

Berend van der Wilk

Citation

Annals of Oncology (2023) 34 (suppl_2): S1254-S1335. 10.1016/S0923-7534(23)04149-2

Authors

B.J. van der Wilk1, B.M. Eyck1, B.P.L. Wijnhoven2, S.M. Lagarde3, C. Rosman4, B.J. Noordman5, M.J. Valkema1, P. Coene6, J. Dekker7, H. Hartgrink8, J. Heisterkamp9, E. Kouwenhoven10, G. Nieuwenhuijzen11, J. Pierie12, J. van Sandick13, M. Sosef14, M. Spaander15, E. van der Zaag16, E. Steyerberg17, J. van Lanschot1

Author affiliations

  • 1 Department Of Surgery, Erasmus MC - Erasmus University Rotterdam, 3000 CA - Rotterdam/NL
  • 2 Department Of Surgery, Erasmus MC, 3000 CA - Rotterdam/NL
  • 3 Department Of Surgery, Erasmus Medical Center, Rotterdam/NL
  • 4 Department Of Surgery, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 5 Department Of Surgery, Erasmus University Medical Center, 3000 CA - Rotterdam/NL
  • 6 Department Of Surgery, Maasstad Ziekenhuis, 3079 DZ - Rotterdam/NL
  • 7 Department Of Surgery, Reinier de Graaf Hospital (Gasthuis), 2625 AD - Delft/NL
  • 8 Department Of Surgery, LUMC-Leiden University Medical Center, 2333 ZA - Leiden/NL
  • 9 Department Of Surgery, ETZ - Elisabeth-TweeSteden Hospital, 5042 AD - Tilburg/NL
  • 10 Department Of Surgery, Ziekenhuisgroep Twente (ZGT), 7609PP - Almelo/NL
  • 11 Department Of Surgery, Catharina Hospital Eindhoven, 5602 ZA - Eindhoven/NL
  • 12 Department Of Surgery, MCL - Medisch Centrum Leeuwarden, 8934 AD - Leeuwarden/NL
  • 13 Department Of Surgery, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 14 Department Of Surgery, Zuyderland Medical Center, 6419 PC - Heerlen/NL
  • 15 Department Of Gastroenterology And Hepatology, Erasmus MC, 3000 CA - Rotterdam/NL
  • 16 Department Of Surgery, Gelre Ziekenhuizen, 7334DZ - Apeldoorn/NL
  • 17 Department Of Biomedical Data Sciences, LUMC-Leiden University Medical Center, 2333 ZA - Leiden/NL

Resources

This content is available to event participants. Login below if you are registered.

Abstract LBA75

Background

One-third of patients with oesophageal cancer has a pathologically complete response after neoadjuvant chemoradiotherapy (nCRT) plus oesophagectomy. Active surveillance may be an alternative for patients with clinically complete response (CCR).

Methods

A noninferiority stepped-wedge cluster randomised trial was performed. Patients with CCR (i.e. no residual disease 6 and 12 weeks after nCRT) underwent active surveillance (surgery only when locoregional regrowth was detected) or standard surgery. Primary endpoint was overall survival (OS) from day of CCR. Noninferiority was defined as Hazard Ratio (HR) <1.77 for mortality in active surveillance after two years. Secondary endpoints were operative outcomes, disease-free survival (DFS), distant dissemination rate and quality of life (HRQOL, EORTC QLQ-C30).

Results

Some 198 patients underwent active surveillance and 111 patients underwent standard surgery. Median follow-up was 34 months in active surveillance and 50 months in standard surgery. OS in active surveillance was noninferior to standard surgery (HR 0.88, 95% upper boundary 1.40, p = 0.007). During active surveillance, 69 patients (35%) maintained CCR, 96 patients (48%) developed locoregional regrowths, and 33 patients (17%) developed distant metastases. R1 rate was 2% in both groups and postoperative 90-day mortality was 4% (active surveillance) versus 5% (standard surgery). Median DFS for active surveillance was 35 (95% CI 31 – 41) versus 49 months (95% CI 38 – NA) for standard surgery (HR 1.35, 95% CI 0.89 – 2.03, p = 0.15). At 30 months after nCRT, 43% of patients with active surveillance versus 34% with standard surgery developed distant metastases (OR 1.45, 95% CI 0.85 – 2.48, p = 0.18). HRQOL was statistically significantly better at six (p = 0.002) and nine months (p = 0.007) for active surveillance.

Conclusions

After a follow-up of two years, patients undergoing active surveillance had noninferior OS and improved short-term HRQOL compared to standard surgery. Postponed esophagectomy for locoregional regrowth was safe. Extended follow-up is required to assess long-term efficacy of active surveillance.

Clinical trial identification

NTR6803 8-11-2017.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study was funded by the Dutch Cancer Society (KWF) and Netherlands Organisation for Health Research and Development (ZonMw).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.